Dr Samantha Walker, Director of Research and Innovation at Asthma + Lung UK, the leading lung charity, discusses the socioeconomic costs of lung conditions and the need for great lung health research.
Sarah MacFadyen, Vice Chair of the Taskforce for Lung Health and Head of Policy and External Affairs at Asthma UK and the British Lung Foundation, says it’s time that tobacco dependency was treated just like any other illness.
Research led by investigators at Massachusetts General Hospital reveals that people who use both e-cigarettes and tobacco cigarettes are more likely to develop respiratory symptoms compared to those using either one alone.
The impact of COVID-19 has proven that we cannot let people with lung conditions continue to be forgotten, says Dr Alison Cook, Chair of the Taskforce for Lung Health.
A research team at MIT have created a machine-learning strategy to identify existing drugs that could be repurposed to fight COVID-19 in elderly patients.
UK Research and Innovation (UKRI) has awarded £3.5 million-worth of funding to help ground-breaking medical research find new ways to diagnose lung cancer earlier.
Phillip P. Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), discusses the use of CytoSorb, a broad-spectrum blood purification technology to treat cytokine storm and hyperinflammation in critically ill COVID-19 patients.
Prof Dr Joost Sluijter, Professor, Cellular and Translational Cardiology at University Medical Center Utrecht shares an in-depth perspective on the needs for innovative treatments for heart failure.
Michael Roth discusses soluble circulating cytokine receptors in chronic inflammatory lung diseases, which he describes as the under-estimated regulators of inflammation and remodelling.
Stephen C Clark, from Newcastle upon Tyne Hospitals NHS Foundation Trust and University of Northumbria in the UK explains idiopathic pulmonary fibrosis, a type of lung disease.
Michael Roth, Research Group Leader at University Hospital Basel asks if fine dust air pollution (PM2.5) is a cause of chronic inflammatory lung diseases and provides a most engaging response.
Daikin reviews whether air pollution in the UK has improved over the years and details how chemical compounds and matter existing in our air pose a threat to our planet.
More can be done at the local, national and EU level to improve COPD diagnosis, support smoking cessation and advance work and living conditions for people living with COPD.
NHS England has announced it has secured a definitive cystic fibrosis drugs agreement with Vertex Pharmaceuticals, to use all three of their UK-licensed medicines.
Steve Jones, Chair Action for Pulmonary Fibrosis and Board Member EU-IPFF and Gisli Jenkins from Nottingham University Hospitals, explain idiopathic pulmonary fibrosis (IPF), an incurable lung disease.
Karen Moor and Marlies Wijsenbeek from the Erasmus Medical Center, Rotterdam explore the role of eHealth tools in idiopathic pulmonary fibrosis care and research.
